Akoya (AKYA) Misses Q1 EPS by 1c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Akoya Reports Record Revenue in the First Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
May 8, 2023 4:05 PM EDTQ1 2023 revenue $21.4 million, 27% y/y growth Reiterating FY 2023 revenue guidance range of $95-98 million
MARLBOROUGH, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (Akoya), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2023.
Akoya started the year strong, highlighted by record quarterly revenue and our 1000th spatial instrument placement in April, the largest installed base in the rapidly growing spatial biology industry, said Brian McKelligon, Chief Executive Officer, Akoya Biosciences. We continue to see robust growth... More
